Hi everyone,
My name’s Kira and I work in the Policy, Evidence and Influencing team at Breast Cancer Now.
We’re really interested to hear from anyone who has received the treatment capivasertib in combination with fulvestrant (also known as Truqap with Faslodex). This combination is used to treat hormone receptor-positive, HER2-negative secondary breast cancer after endocrine treatment. You may have received it as part of a clinical trial.
The combination is being assessed by the Scottish Medicines Consortium (SMC) to see if it should be made available through NHSScotland and we would love to hear your views to help shape our submission.
It’s crucial that the SMC hears the voices of patients as part of their assessment. If you’d like to share your views on this treatment, please email policy@breastcancernow.org by 5pm on Thursday 5 June. Your views will be shared completely anonymously.
Thank you!
Kira